Industry sources reveal drug companies have stopped negotiating listings on the PBS and in some cases are considering not ...

Pfizer's CEO discussed the extensive due diligence the company has conducted on the 3SBio PD-1xVEGF deal. | Pfizer's CEO ...

President Isaac Herzog and Genesis Prize Foundation chairman Stan Polovets presented the award, praising Milei as a “moral ...

Deep Apple Therapeutics Inc. could bring in as much as $812 million in a new collaboration and license deal with Novo Nordisk A/S. The total includes an unspecified up-front payment, research costs ...

Pfizer Inc. (NYSE:PFE) is one of the best wide moat stocks to buy now. On June 9, Pfizer, along with other drug manufacturers ...

Pfizer’s CEO Albert Bourla disclosed that the company recently met with the Trump administration to discuss lowering U.S.

Sbio Inc. reported interim phase II study results of its PD-1/VEGF bispecific antibody, SSGJ-707 – a “fabulous” asset, according to Pfizer Inc. CEO Albert Bourla, that landed in Pfizer’s cancer ...

BioSpace did a deep dive into executive pay, examining the highest compensation packages, pay ratios and golden ...

Pharmaceutical executives say that the Trump administration has not provided enough details as to how it will achieve the ...

(Reuters) -Talks with the Trump administration about lowering U.S. drug prices have so far not provided clarity on when and ...

As President Donald Trump vows to bridge the drug pricing gap between the U.S. and other developed countries with his “most ...

Pfizer CEO Albert Bourla, Ph.D., has pulled back the curtain on his $1.25 billion bet on a PD-1xVEGF bispecific, revealing ...